CRISPR Therapeutics AG (CRSP) Insider Trading
Over the last 3 months, CRSP insiders made 0 open-market buys and 1 sale, a net sale of -$211K (SEC Form 4). Over the last 6 months, 351 institutions increased and 256 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
1
Net (3m)
-$210.6K
Insider trades by month Buys Sells
Oct
Dec
Jan
Feb
Mar
Jun
Context3-month price +14.7%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 9, 2026 | High Katherine Adirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Greene Johndirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Rommel Christiandirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Fardis Mariadirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Behbahani Alidirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Morrison Briggsdirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | George Simeondirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Mahatme Sandeshdirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Treco Douglas Adirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Fleming Harold Edwarddirector | Grant | 13,000 | $51.84 |
| Jun 2, 2026 | Patel Naimishofficer: Chief Medical Officer | Grant | 22,000 | — |
| Jun 2, 2026 | KASINGER JAMES R.officer: General Counsel and Secretary | Grant | 17,000 | — |
| Jun 2, 2026 | Prasad Rajuofficer: Chief Financial Officer | Grant | 19,500 | — |
| Jun 1, 2026 | Patel Naimishofficer: Chief Medical Officer | Option | 10,000 | — |
| Jun 1, 2026 | Patel Naimishofficer: Chief Medical Officer | Sell | 3,786 | $55.62 |
| Mar 24, 2026 | Prasad Rajuofficer: Chief Financial Officer | Sell | 3,708 | $46.78 |
| Mar 24, 2026 | Prasad Rajuofficer: Chief Financial Officer | Option | 6,250 | — |
| Mar 24, 2026 | KASINGER JAMES R.officer: General Counsel and Secretary | Grant | 25,000 | — |
| Mar 24, 2026 | KASINGER JAMES R.officer: General Counsel and Secretary | Sell | 3,182 | $46.78 |
| Mar 24, 2026 | Kulkarni Samarthdirector, officer: Chief Executive Officer | Grant | 114,249 | $46.24 |
| Mar 24, 2026 | Patel Naimishofficer: Chief Medical Officer | Grant | 30,000 | — |
| Mar 24, 2026 | Kulkarni Samarthdirector, officer: Chief Executive Officer | Sell | 10,020 | $46.78 |
| Mar 24, 2026 | Prasad Rajuofficer: Chief Financial Officer | Grant | 27,500 | — |
| Mar 24, 2026 | Kulkarni Samarthdirector, officer: Chief Executive Officer | Grant | 81,875 | — |
| Mar 24, 2026 | KASINGER JAMES R.officer: General Counsel and Secretary | Option | 6,250 | — |
| Mar 24, 2026 | Prasad Rajuofficer: Chief Financial Officer | Grant | 38,499 | $46.24 |
| Mar 24, 2026 | Patel Naimishofficer: Chief Medical Officer | Grant | 38,499 | $46.24 |
| Mar 24, 2026 | KASINGER JAMES R.officer: General Counsel and Secretary | Grant | 38,499 | $46.24 |
| Mar 24, 2026 | Kulkarni Samarthdirector, officer: Chief Executive Officer | Option | 19,687 | — |
| Mar 17, 2026 | Prasad Rajuofficer: Chief Financial Officer | Option | 6,875 | — |
Source: CRSP SEC Form 4 filings, latest Jun 9, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their CRSP positions over the last 6 months (SEC Form 13F).
Increased
351
New positions
165
Reduced
256
Sold out
120
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| ARK INVESTMENT MANAGEMENT LLC | Increased | 11.3M | May 12, 2026 |
| ARK INVESTMENT MANAGEMENT LLC | Increased | 10.5M | Feb 11, 2026 |
| BLACKROCK, INC. | Increased | 7.7M | May 13, 2026 |
| BLACKROCK, INC. | Increased | 7.5M | Feb 12, 2026 |
| ORBIS ALLAN GRAY LTD | Increased | 6.1M | May 15, 2026 |
| ORBIS ALLAN GRAY LTD | Increased | 6.0M | Feb 17, 2026 |
| CAPITAL INTERNATIONAL INVESTORS | Increased | 5.9M | Feb 11, 2026 |
| CAPITAL WORLD INVESTORS | New Position | 4.7M | May 13, 2026 |
| STATE STREET CORP | Increased | 4.0M | May 15, 2026 |
| STATE STREET CORP | Reduced | 3.8M | Feb 13, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | Reduced | 3.2M | Feb 19, 2026 |
| GSK PLC | Unchanged | 3.2M | May 14, 2026 |
| GSK PLC | New Position | 3.2M | Feb 12, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | Reduced | 3.0M | May 15, 2026 |
| UBS GROUP AG | Increased | 2.5M | Jan 29, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.